My­ovan­t's uter­ine fi­broid drug looks com­pet­i­tive in PhI­II — but can they van­quish mighty Ab­b­Vie?

Vivek Ra­maswamy’s My­ovant $MY­OV has close­ly matched its pos­i­tive first round of Phase III da­ta for their uter­ine fi­broid drug re­l­u­golix, set­ting up a head-to-head ri­val­ry with phar­ma gi­ant Ab­b­Vie as the lit­tle biotech steers to the mar­ket with a planned fil­ing in Q4.

Here’s how My­ovant plans to pre­vail over the Ab­b­Vie $AB­BV em­pire.

In the study, 71.2% of women re­ceiv­ing once-dai­ly re­l­u­golix com­bi­na­tion ther­a­py achieved the clin­i­cal re­sponse they were look­ing for, com­pared to on­ly 14.7% in the con­trol arm. The da­ta com­fort­ably re­flect­ed the same out­comes in the first Phase III — 73.4% of women re­ceiv­ing once-dai­ly oral re­l­u­golix com­bi­na­tion ther­a­py achieved the re­spon­der cri­te­ria com­pared with 18.9% of women re­ceiv­ing place­bo — which will re­as­sure reg­u­la­tors that they are get­ting the care­ful­ly ran­dom­ized da­ta that qual­i­fies for the FDA’s gold stan­dard for suc­cess.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER